41. Secukinumab sustains good efficacy and favourable safety in moderate‐to‐severe psoriasis after up to 3 years of treatment: results from a double‐blind extension study. (1st October 2017) Authors: Bissonnette, R.; Luger, T.; Thaçi, D.; Toth, D.; Messina, I.; You, R.; Guana, A.; Fox, T.; Papavassilis, C.; Gilloteau, I.; Mrowietz, U. Journal: British journal of dermatology Issue: Volume 177:Number 4(2017) Page Start: 1033 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
42. Secukinumab sustains good efficacy and favourable safety in moderate‐to‐severe psoriasis after up to 3 years of treatment: results from a double‐blind extension study. (4th September 2017) Authors: Bissonnette, R.; Luger, T.; Thaçi, D.; Toth, D.; Messina, I.; You, R.; Guana, A.; Fox, T.; Papavassilis, C.; Gilloteau, I.; Mrowietz, U. Journal: British journal of dermatology Issue: Volume 177:Number 4(2017) Page Start: 1033 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
43. Sensitivity of clinician‐assessed efficacy outcome measurement instruments in trials of topical therapies for atopic dermatitis: a systematic review and meta‐analysis. (22nd November 2021) Authors: Légaré, S.; Chagnon, M.; Palijan, A.; Kojok, K.; Bissonnette, R. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 2(2022) Page Start: 196 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
44. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study. (6th May 2019) Authors: Bissonnette, R.; Maari, C.; Forman, S.; Bhatia, N.; Lee, M.; Fowler, J.; Tyring, S.; Pariser, D.; Sofen, H.; Dhawan, S.; Zook, M.; Zammit, D.J.; Usansky, H.; Denis, L.; Rao, N.; Song, T.; Pavel, A.B.; Guttman‐Yassky, E. Journal: British journal of dermatology Issue: Volume 181:Number 4(2019) Page Start: 733 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
45. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study. (1st October 2019) Authors: Bissonnette, R.; Maari, C.; Forman, S.; Bhatia, N.; Lee, M.; Fowler, J.; Tyring, S.; Pariser, D.; Sofen, H.; Dhawan, S.; Zook, M.; Zammit, D.J.; Usansky, H.; Denis, L.; Rao, N.; Song, T.; Pavel, A.B.; Guttman‐Yassky, E. Journal: British journal of dermatology Issue: Volume 181:Number 4(2019) Page Start: 733 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
46. THU0412 Cardiovascular Outcomes in Patients with Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-Analyses. (10th June 2014) Authors: McFarlane, A.; Roubille, C.; Richer, V.; Starnino, T.; McCourt, C.; Fleming, P.; Siu, S.; Kraft, J.; Lynde, C.; Pope, J.; Gulliver, W.; Dutz, J.; Bessette, L.; Bissonnette, R.; Haraoui, B.; Keeling, S.O. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 324 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
47. Tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: long‐term safety and efficacy in an open‐label extension study. (1st October 2018) Authors: Valenzuela, F.; Korman, N.J.; Bissonnette, R.; Bakos, N.; Tsai, T.‐F.; Harper, M.K.; Ports, W.C.; Tan, H.; Tallman, A.; Valdez, H.; Gardner, A.C. Journal: British journal of dermatology Issue: Volume 179:Number 4(2018) Page Start: 853 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
48. Tofacitinib withdrawal and retreatment in moderate‐to‐severe chronic plaque psoriasis: a randomized controlled trial. (1st May 2015) Authors: Bissonnette, R.; Iversen, L.; Sofen, H.; Griffiths, C.E.M.; Foley, P.; Romiti, R.; Bachinsky, M.; Rottinghaus, S.T.; Tan, H.; Proulx, J.; Valdez, H.; Gupta, P.; Mallbris, L.; Wolk, R. Journal: British journal of dermatology Issue: Volume 172:Number 5(2015:May) Page Start: 1395 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
49. Tofacitinib withdrawal and retreatment in moderate‐to‐severe chronic plaque psoriasis: a randomized controlled trial. (2nd April 2015) Authors: Bissonnette, R.; Iversen, L.; Sofen, H.; Griffiths, C.E.M.; Foley, P.; Romiti, R.; Bachinsky, M.; Rottinghaus, S.T.; Tan, H.; Proulx, J.; Valdez, H.; Gupta, P.; Mallbris, L.; Wolk, R. Journal: British journal of dermatology Issue: Volume 172:Number 5(2015:May) Page Start: 1395 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
50. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. (1st November 2016) Authors: Bissonnette, R.; Papp, K.A.; Poulin, Y.; Gooderham, M.; Raman, M.; Mallbris, L.; Wang, C.; Purohit, V.; Mamolo, C.; Papacharalambous, J.; Ports, W.C. Journal: British journal of dermatology Issue: Volume 175:Number 5(2016) Page Start: 902 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗